ObjectiveTo investigate the effect of entecavir combined with sorafenib on the efficacy of transcatheter chemoembolization (TACE) for treating patients with hepatocellular carcinoma. MethodsFrom January 2011 to December 2017, 100 patients with hepatocellular carcinoma hospitalized and treated in Gastroenterology Department of our hospital were selected, and were randomly divided into observation group and control group, with 50 cases in each group. Both groups were received TACE treatment, based on which the control group was administered entecavir after operation, whereas the observation group was administered entecavir and solanib after operation. The clinical efficacy was compared between the two groups. ResultsAfter 6 months of treatment, the total effective rate in the observation group was significantly higher than that in the control group (88% vs. 46.0%), and the clinical efficacy was superior to that in the control group, with the statistically significant differences (P＜0.05). The levels of ALT and TBIL significantly increased, whereas the levels of HBV-DNA and AFP significantly decreased. In comparison with the control group, patients in the observation group obtained higher ALT and TBIL, while a lower AFP level, with the statistically significant differences (P＜0.05). After 2 years of follow-up, the survival rates of the observation group at 12 and 18 months (66.0% and 30.0%, respectively) were significantly higher than those of the control group (44.0% and 12.0%, respectively), with the statistically significant differences (P＜0.05). ConclusionEntecavir combined with sorafenib can effectively improve the clinical effect of TACE treatment in patients with hepatocellular carcinoma, which can significantly decrease the levels of HBV-DNA and AFP; meanwhile, it can increase the survival rates of 12 months and 18 months, for it provides a relatively effective method for hepatocellular carcinoma patients who cannot receive surgical resection.

无